

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT


Robert M. LORENCE et al

FILING DATE

TC/A.U.

June 16, 1994

1648



(Use General sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

eh	Povlsen, C.O.; "Status of Chemotherapy, Radiotherapy, Endocrine Therapy, and Immunotherapy Studies of Human Cancer in the Nude Mouse"; <i>The Nude Mouse in Experimental and Clinical Research</i> ; Academic Press, New York, San Francisco, London; pp. 437-457 (1978).
	Thorne, S.H., et al; "Future Directions for the Field of Oncolytic Virotherapy: A Perspective on the Use of Vaccinia Virus"; <i>Expert Opin. Biol. Ther.</i> ; Vol. 4, No. 8; pp 1307-1321 (2004).
	Poster (ASCO Meeting); "Slow Intravenous Infusion of PV701, An Oncolytic Virus: Final Results of a Phase Study"; <i>2004 Am. Soc. Clin. Oncology (ASCO) Mtg.</i>
	Schirrmacher, V., et al; "Virus Potentiation of Tumor Vaccine T-Cell Stimulatory Capacity Requires Cell Surface Binding but not Infection"; <i>Clinical Cancer Research</i> ; Vol. 3; pp. 1135-1148 (1997).
	Zorn, U., et al; "Induction of Cytokines and Cytotoxicity Against Tumor Cells by Newcastle Disease Virus"; <i>Cancer Biotherapy</i> ; Vol. 9, No. 3; pp. 225-235 (1994).
	Zorn, U., et al; "Active Specific Immunotherapy of Renal Cell Carcinoma: Cellular and Humoral Immune Responses"; <i>Cancer Biotherapy & Radiopharmaceuticals</i> ; Vol. 12, No. 3; pp. 157-165 (1997).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 4; C-584 p. 150 (1985).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 5; 534 p. 137 (1986).
	Krishnamurthy, S., et al; "Newcastle Disease Virus as an Oncolytic Agent: Mechanism of Viral Infection, Growth and Oncolysis"; <i>American Society for Virology 21st Annual Meeting, University of Kentucky, Lexington, KY, July 20-24, 2002, Scientific Program and Abstracts</i> ; p. 90.
	Batliwalla, F.M., et al; "A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alternations in the CD8 T Cell Repertoire"; <i>Molecular Medicine</i> ; Vol. 4; pp. 783-794 (1998).
	Bonaccorsi, P., et al; "Management of High-risk Melanoma"; <i>Medical Dermatology</i> ; Vol. 19, No. 4; pp 727-735 (2001).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.